{
    "2O9.F": {
        "short_name": "RENALYTIX AI PLC LS-,0025",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "63V.F": {
        "short_name": "VERICI DX PLC  LS-,001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Penarth"
    },
    "ABDX.L": {
        "short_name": "ABINGDON HEALTH PLC ORD 0.025P",
        "long_name": "Abingdon Health Plc",
        "summary": "Abingdon Health Plc, a technology-enabled lateral flow diagnostics company, develops, manufactures, and markets medical diagnostics worldwide. The company offers AbC-19 Rapid Test, a COVID-19 neutralizing antibody test; nucleic acid lateral flow immunoassays; and Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. It also provides lateral flow development, manufacturing, and reader customization services. Additionally, the company provides consultancy services to businesses in the diagnostics sector. Abingdon Health Plc has a collaboration and co-marketing agreement with Abcam plc. The company was founded in 2008 and is headquartered in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "AGL.L": {
        "short_name": "ANGLE PLC ORD 10P",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "ALNOV.PA": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "ANPCY": {
        "short_name": "ANGLE",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "BQB1.F": {
        "short_name": "YOURGENE HEALTH  LS 0,001",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "D6M.F": {
        "short_name": "GENEDRIVE PLC  LS -,015",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "DWV.F": {
        "short_name": "ANGLE PLC  LS-,10",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "EKF.L": {
        "short_name": "EKF DIAGNOSTICS HOLDINGS PLC OR",
        "long_name": "EKF Diagnostics Holdings plc",
        "summary": "EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company offers Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; sTNFRr1, a predictive marker of end stage renal disease; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and RaPET Serology immunoassay kits, as well as reagents, calibrators, standards, and controls. Additionally, it provides contract manufacturing services, as well as services and distributes third party company's products. It sells its products directly to hospitals, laboratories, and government agencies, as well as through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "GDR.L": {
        "short_name": "GENEDRIVE PLC ORD 1.5P",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "NCYT.L": {
        "short_name": "NOVACYT S.A. EUR1/15TH (CDI)",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "NVYTF": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "NYZ.F": {
        "short_name": "NOVACYT  EO-,0667",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "PI2.F": {
        "short_name": "PROTEOME SCIENCES  LS-01",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro; and manufactures small and protein-reactive chemical reagents. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay for multi-protein biomarker panels. It primarily serves pharmaceutical and biotechnology companies, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "PMSNF": {
        "short_name": "PROTEOME SCIENCES",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro; and manufactures small and protein-reactive chemical reagents. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay for multi-protein biomarker panels. It primarily serves pharmaceutical and biotechnology companies, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "PRM.L": {
        "short_name": "PROTEOME SCIENCES PLC ORD 1P",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro; and manufactures small and protein-reactive chemical reagents. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay for multi-protein biomarker panels. It primarily serves pharmaceutical and biotechnology companies, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "RENX.L": {
        "short_name": "RENALYTIX AI PLC ORD 0.25P",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RNLX": {
        "short_name": "Renalytix AI plc",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RTNXF": {
        "short_name": "RENALYTIX AI PLC",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "VRCI.L": {
        "short_name": "VERICI DX PLC ORD GBP0.001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Penarth"
    },
    "YGEN.L": {
        "short_name": "YOURGENE HEALTH PLC ORD 0.1P",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Manchester"
    }
}